Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 16, 2023; 11(29): 7170-7178
Published online Oct 16, 2023. doi: 10.12998/wjcc.v11.i29.7170
Rituximab combined with Bruton tyrosine kinase inhibitor to treat elderly diffuse large B-cell lymphoma patients: Two case reports
Cang-Jian Zhang, Min-Lei Zhao
Cang-Jian Zhang, Min-Lei Zhao, Department of Hematology, Lishui Municipal Central Hospital, Lishui 323000, Zhejiang Province, China
Author contributions: Zhang CJ designed the report and wrote the paper; Zhao ML collected the patient’s clinical data.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Min-Lei Zhao, Doctor, Department of Hematology, Lishui Municipal Central Hospital, No. 289 Kuocang Road, Lishui 323000, Zhejiang Province, China. minleizhao@163.com
Received: June 26, 2023
Peer-review started: June 26, 2023
First decision: August 16, 2023
Revised: August 25, 2023
Accepted: September 22, 2023
Article in press: September 22, 2023
Published online: October 16, 2023
Processing time: 107 Days and 0.5 Hours
Abstract
BACKGROUND

Diffuse large B-cell lymphoma (DLBCL) is a common aggressive non-Hodgkin's lymphoma (NHL), accounting for 30%-40% of adult NHLs. This report aims to explore the efficacy and safety of rituximab combined with Bruton tyrosine kinase inhibitors (BTKis) in the treatment of elderly patients with DLBCL.

CASE SUMMARY

The clinical data of two elderly patients with DLBCL who received rituximab combined with BTKi in our hospital were retrospectively analyzed, and the literature was reviewed. The patients were treated with chemotherapy using the R-miniCHOP regimen for two courses. Then, they received rituximab in combination with BTKi.

CONCLUSION

The treatment experience in these cases demonstrates the potential efficacy of rituximab combined with BTKi to treat elderly DLBCL patients, thus providing a new treatment strategy.

Keywords: Diffuse large B-cell lymphoma; Rituximab; Bruton tyrosine kinase inhibitors; Elderly patients; Case report

Core Tip: The clinical data of two elderly patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab combined with Bruton tyrosine kinase (BTK) inhibitor (BTKi) in our hospital were retrospectively analyzed, and the literature was reviewed. The patients were treated with chemotherapy using the R-miniCHOP regimen for 2 courses. Then, they received rituximab in combination with BTKi. The treatment experience in these patients demonstrates the potential efficacy of rituximab combined with BTKi to treat elderly DLBCL patients, thus providing a new treatment strategy.